ATE266044T1 - Oral wirksame peptide, die zellschädigung und zelltod verhindern - Google Patents

Oral wirksame peptide, die zellschädigung und zelltod verhindern

Info

Publication number
ATE266044T1
ATE266044T1 AT00957607T AT00957607T ATE266044T1 AT E266044 T1 ATE266044 T1 AT E266044T1 AT 00957607 T AT00957607 T AT 00957607T AT 00957607 T AT00957607 T AT 00957607T AT E266044 T1 ATE266044 T1 AT E266044T1
Authority
AT
Austria
Prior art keywords
active core
core site
cell death
methods
reducing
Prior art date
Application number
AT00957607T
Other languages
English (en)
Inventor
Douglas E Brenneman
Illana Gozes
Catherine Y Spong
Albert Pinhasov
Eliezer Giladi
Original Assignee
Univ Ramot
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Us Health filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE266044T1 publication Critical patent/ATE266044T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT00957607T 1999-08-18 2000-08-17 Oral wirksame peptide, die zellschädigung und zelltod verhindern ATE266044T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14995699P 1999-08-18 1999-08-18
PCT/US2000/022861 WO2001012654A2 (en) 1999-08-18 2000-08-17 Orally active peptides that prevent cell damage and death

Publications (1)

Publication Number Publication Date
ATE266044T1 true ATE266044T1 (de) 2004-05-15

Family

ID=22532517

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957607T ATE266044T1 (de) 1999-08-18 2000-08-17 Oral wirksame peptide, die zellschädigung und zelltod verhindern

Country Status (7)

Country Link
EP (1) EP1206489B1 (de)
AT (1) ATE266044T1 (de)
AU (1) AU761597B2 (de)
CA (1) CA2381981A1 (de)
DE (1) DE60010478T2 (de)
ES (1) ES2220522T3 (de)
WO (1) WO2001012654A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384908B1 (en) 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
EP1285000B1 (de) 2000-05-31 2004-11-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
US20040235747A1 (en) * 2003-01-02 2004-11-25 Ramot At Tel-Aviv University Ltd. Methods of treating and/or preventing autoimmune diseases
US7960334B2 (en) 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
WO2005099741A1 (ja) * 2004-04-08 2005-10-27 Noevir Co., Ltd. 運動ニューロン疾患治療薬
AU2006227528B2 (en) * 2005-03-23 2011-05-26 Allon Therapeutics, Inc. Use of ADNF polypeptides for treating peripheral neurotoxicity
CA2638827A1 (en) * 2006-02-24 2007-08-30 Illana Gozes Protection of the retina against laser injury by adnf peptides such as nap and sal
EP2125873B1 (de) 2007-01-11 2011-09-14 Ramot at Tel Aviv University Ltd. Tau Peptidmimetikum zur Behandlung von neurodegenerativen Erkrankungen
AU2008291652A1 (en) * 2007-08-24 2009-03-05 Allon Therapeutics Inc. Neuroprotection using NAP-like and SAL-like peptide mimetics
US8586548B2 (en) 2009-08-17 2013-11-19 Ramot At Tel-Aviv University, Ltd. NAP alpha-aminoisobutyric acid analog with neuroprotective activity
US20130053320A1 (en) 2010-02-12 2013-02-28 Ramot At Tel-Aviv University, Ltd. Treatment of anemia by adnp and adnf polypeptides
WO2012015910A2 (en) 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases
WO2013171595A1 (en) 2012-05-16 2013-11-21 Ramot At Tel-Aviv University Ltd. Novel compounds and methods for inhibiting cell death
WO2015010442A1 (en) 2013-07-24 2015-01-29 The Chinese University Of Hong Kong Biomarkers for premature birth
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
ES2975662T3 (es) 2018-10-31 2024-07-11 Univ Arizona Biomarcadores y métodos de uso para la lesión pulmonar inducida por radiación
EP4247427A4 (de) 2020-11-19 2025-04-09 The Chinese University of Hong Kong Risikobeurteilung für kolorektale adenomrezidiven durch nichtinvasive mittel

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0966533T3 (da) * 1997-02-07 2010-01-04 Us Gov Health & Human Serv Aktivitetsafhængig neurotrof faktor III (ADNF III).

Also Published As

Publication number Publication date
DE60010478T2 (de) 2005-06-09
CA2381981A1 (en) 2001-02-22
EP1206489B1 (de) 2004-05-06
WO2001012654A3 (en) 2002-01-24
WO2001012654A2 (en) 2001-02-22
AU761597B2 (en) 2003-06-05
AU6920100A (en) 2001-03-13
ES2220522T3 (es) 2004-12-16
DE60010478D1 (de) 2004-06-09
EP1206489A2 (de) 2002-05-22

Similar Documents

Publication Publication Date Title
DE60010478D1 (de) Oral wirksame peptide, die zellschädigung und zelltod verhindern
ITFI930247A1 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
BR0116587A (pt) Uso de uma eritropoietina, composição farmacêutica, métodos para proteger, manter ou realçar a viabilidade de uma célula, tecido ou órgão isolado de um corpo mamìfero, para facilitar a trancitose de uma molécula através de uma barreira endotelial celular em um mamìfero, composição para transportar uma molécula via trancitose através de uma barreira endotelial celular, e, composição
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
WO2002048183A3 (en) Compositions of peptide crystals
NZ505073A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant, useful for treating allergic, inflammatory and intestinal diseases
HUP0100669A3 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
ATE215081T1 (de) Gonadotropin releasing hormon- antagonisten
SI0991407T2 (en) Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
TR199501669A1 (tr) Peptid ve proteinlerin aerosol formülasyonlari.
NO20001567D0 (no) Bioadhesive sammensetninger og fremgangsmåter for topisk administrering av aktive midler
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
ATE329608T1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
WO2000053217A3 (en) Prevention of fetal alcohol syndrome and neuronal cell death with adnf polypeptides
NO970282L (no) Adénovirus omfattende et gen som koder for glutationperoksydase
BR9811094A (pt) Agente terapêutico para tumores linfáticos
CA2338794A1 (en) New oral formulation for 5-ht4 agonists or antagonists
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
WO2006023665A3 (en) Il-1 antagonist formulations
PT1154786E (pt) Metodos e composicoes para alterar a secrecao de muco
DE60135261D1 (de) Arzneimittel, welches ein Peptid kleiner oder mittlerer Grösse enthält
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
ATE342276T1 (de) Nährstoffe aus sojabohnenprotein
IT1256623B (it) Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties